Cytek Biosciences Dividends
| CTKB Stock | USD 4.24 0.07 1.68% |
The current year's Dividend Paid And Capex Coverage Ratio is expected to grow to 6.80, whereas Dividends Paid is forecasted to decline to about 922.4 K. Cytek Biosciences' past performance could be the main factor of why investors trade Cytek Biosciences stock today. Investors should clearly understand every aspect of the Cytek Biosciences dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Cytek Biosciences' dividend schedule and payout information. Cytek Biosciences dividends can also provide a clue to the current valuation of Cytek Biosciences.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 1.7 M | 922.4 K | |
| Dividend Paid And Capex Coverage Ratio | 6.48 | 6.80 |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Cytek Biosciences must own a stock before its ex-dividend date to receive its next dividend.
Cytek Biosciences Dividends Paid Over Time
Today, most investors in Cytek Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cytek Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's dividends paid growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cytek Biosciences dividends paid as a starting point in their analysis.
The total amount of dividends that a company has paid out to its shareholders over a specific period. Dividends Paid |
| Timeline |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. Projected growth potential of Cytek fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytek Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.735 | Earnings Share (0.11) | Revenue Per Share | Quarterly Revenue Growth 0.015 | Return On Assets |
Investors evaluate Cytek Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytek Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Cytek Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Cytek Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytek Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytek Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.